Accuracy of Continuous Glucose Monitoring in Hemodialysis Patients With Diabetes

In the general population, continuous glucose monitoring (CGM) provides convenient and less-invasive glucose measurements than conventional self-monitored blood glucose and results in reduced hypo-/hyperglycemia and increased time-in-target glucose range. However, accuracy of CGM versus blood glucos...

Full description

Saved in:
Bibliographic Details
Published inDiabetes care
Main Authors Narasaki, Yoko, Kalantar-Zadeh, Kamyar, Daza, Andrea C, You, Amy S, Novoa, Alejandra, Peralta, Renal Amel, Siu, Man Kit Michael, Nguyen, Danh V, Rhee, Connie M
Format Journal Article
LanguageEnglish
Published United States 30.08.2024
Online AccessGet full text

Cover

Loading…
Abstract In the general population, continuous glucose monitoring (CGM) provides convenient and less-invasive glucose measurements than conventional self-monitored blood glucose and results in reduced hypo-/hyperglycemia and increased time-in-target glucose range. However, accuracy of CGM versus blood glucose is not well established in hemodialysis patients. Among 31 maintenance hemodialysis patients with diabetes hospitalized from October 2020-May 2021, we conducted protocolized glucose measurements using Dexcom G6 CGM versus blood glucose, with the latter measured before each meal and at night, plus every 30-min during hemodialysis. We examined CGM-blood glucose correlations and agreement between CGM versus blood glucose using Bland-Altman plots, percentage of agreement, mean and median absolute relative differences (ARDs), and consensus error grids. Pearson and Spearman correlations for averaged CGM versus blood glucose levels were 0.84 and 0.79, respectively; Bland-Altman showed the mean difference between CGM and blood glucose was ∼+15 mg/dL. Agreement rates using %20/20 criteria were 48.7%, 47.2%, and 50.2% during the overall, hemodialysis, and nonhemodialysis periods, respectively. Mean ARD (MARD) was ∼20% across all time periods; median ARD was 19.4% during the overall period and was slightly lower during nonhemodialysis (18.2%) versus hemodialysis periods (22.0%). Consensus error grids showed nearly all CGM values were in clinically acceptable zones A (no harm) and B (unlikely to cause significant harm). In hemodialysis patients with diabetes, although MARD values were higher than traditional optimal analytic performance thresholds, error grids showed nearly all CGM values were in clinically acceptable zones. Further studies are needed to determine whether CGM improves outcomes in hemodialysis patients.
AbstractList OBJECTIVE In the general population, continuous glucose monitoring (CGM) provides convenient and less-invasive glucose measurements than conventional self-monitored blood glucose and results in reduced hypo-/hyperglycemia and increased time-in-target glucose range. However, accuracy of CGM versus blood glucose is not well established in hemodialysis patients. RESEARCH DESIGN AND METHODS Among 31 maintenance hemodialysis patients with diabetes hospitalized from October 2020–May 2021, we conducted protocolized glucose measurements using Dexcom G6 CGM versus blood glucose, with the latter measured before each meal and at night, plus every 30-min during hemodialysis. We examined CGM-blood glucose correlations and agreement between CGM versus blood glucose using Bland-Altman plots, percentage of agreement, mean and median absolute relative differences (ARDs), and consensus error grids. RESULTS Pearson and Spearman correlations for averaged CGM versus blood glucose levels were 0.84 and 0.79, respectively; Bland-Altman showed the mean difference between CGM and blood glucose was ∼+15 mg/dL. Agreement rates using %20/20 criteria were 48.7%, 47.2%, and 50.2% during the overall, hemodialysis, and nonhemodialysis periods, respectively. Mean ARD (MARD) was ∼20% across all time periods; median ARD was 19.4% during the overall period and was slightly lower during nonhemodialysis (18.2%) versus hemodialysis periods (22.0%). Consensus error grids showed nearly all CGM values were in clinically acceptable zones A (no harm) and B (unlikely to cause significant harm). CONCLUSIONS In hemodialysis patients with diabetes, although MARD values were higher than traditional optimal analytic performance thresholds, error grids showed nearly all CGM values were in clinically acceptable zones. Further studies are needed to determine whether CGM improves outcomes in hemodialysis patients.
In the general population, continuous glucose monitoring (CGM) provides convenient and less-invasive glucose measurements than conventional self-monitored blood glucose and results in reduced hypo-/hyperglycemia and increased time-in-target glucose range. However, accuracy of CGM versus blood glucose is not well established in hemodialysis patients. Among 31 maintenance hemodialysis patients with diabetes hospitalized from October 2020-May 2021, we conducted protocolized glucose measurements using Dexcom G6 CGM versus blood glucose, with the latter measured before each meal and at night, plus every 30-min during hemodialysis. We examined CGM-blood glucose correlations and agreement between CGM versus blood glucose using Bland-Altman plots, percentage of agreement, mean and median absolute relative differences (ARDs), and consensus error grids. Pearson and Spearman correlations for averaged CGM versus blood glucose levels were 0.84 and 0.79, respectively; Bland-Altman showed the mean difference between CGM and blood glucose was ∼+15 mg/dL. Agreement rates using %20/20 criteria were 48.7%, 47.2%, and 50.2% during the overall, hemodialysis, and nonhemodialysis periods, respectively. Mean ARD (MARD) was ∼20% across all time periods; median ARD was 19.4% during the overall period and was slightly lower during nonhemodialysis (18.2%) versus hemodialysis periods (22.0%). Consensus error grids showed nearly all CGM values were in clinically acceptable zones A (no harm) and B (unlikely to cause significant harm). In hemodialysis patients with diabetes, although MARD values were higher than traditional optimal analytic performance thresholds, error grids showed nearly all CGM values were in clinically acceptable zones. Further studies are needed to determine whether CGM improves outcomes in hemodialysis patients.
In the general population, continuous glucose monitoring (CGM) provides convenient and less-invasive glucose measurements than conventional self-monitored blood glucose and results in reduced hypo-/hyperglycemia and increased time-in-target glucose range. However, accuracy of CGM versus blood glucose is not well established in hemodialysis patients.OBJECTIVEIn the general population, continuous glucose monitoring (CGM) provides convenient and less-invasive glucose measurements than conventional self-monitored blood glucose and results in reduced hypo-/hyperglycemia and increased time-in-target glucose range. However, accuracy of CGM versus blood glucose is not well established in hemodialysis patients.Among 31 maintenance hemodialysis patients with diabetes hospitalized from October 2020-May 2021, we conducted protocolized glucose measurements using Dexcom G6 CGM versus blood glucose, with the latter measured before each meal and at night, plus every 30-min during hemodialysis. We examined CGM-blood glucose correlations and agreement between CGM versus blood glucose using Bland-Altman plots, percentage of agreement, mean and median absolute relative differences (ARDs), and consensus error grids.RESEARCH DESIGN AND METHODSAmong 31 maintenance hemodialysis patients with diabetes hospitalized from October 2020-May 2021, we conducted protocolized glucose measurements using Dexcom G6 CGM versus blood glucose, with the latter measured before each meal and at night, plus every 30-min during hemodialysis. We examined CGM-blood glucose correlations and agreement between CGM versus blood glucose using Bland-Altman plots, percentage of agreement, mean and median absolute relative differences (ARDs), and consensus error grids.Pearson and Spearman correlations for averaged CGM versus blood glucose levels were 0.84 and 0.79, respectively; Bland-Altman showed the mean difference between CGM and blood glucose was ∼+15 mg/dL. Agreement rates using %20/20 criteria were 48.7%, 47.2%, and 50.2% during the overall, hemodialysis, and nonhemodialysis periods, respectively. Mean ARD (MARD) was ∼20% across all time periods; median ARD was 19.4% during the overall period and was slightly lower during nonhemodialysis (18.2%) versus hemodialysis periods (22.0%). Consensus error grids showed nearly all CGM values were in clinically acceptable zones A (no harm) and B (unlikely to cause significant harm).RESULTSPearson and Spearman correlations for averaged CGM versus blood glucose levels were 0.84 and 0.79, respectively; Bland-Altman showed the mean difference between CGM and blood glucose was ∼+15 mg/dL. Agreement rates using %20/20 criteria were 48.7%, 47.2%, and 50.2% during the overall, hemodialysis, and nonhemodialysis periods, respectively. Mean ARD (MARD) was ∼20% across all time periods; median ARD was 19.4% during the overall period and was slightly lower during nonhemodialysis (18.2%) versus hemodialysis periods (22.0%). Consensus error grids showed nearly all CGM values were in clinically acceptable zones A (no harm) and B (unlikely to cause significant harm).In hemodialysis patients with diabetes, although MARD values were higher than traditional optimal analytic performance thresholds, error grids showed nearly all CGM values were in clinically acceptable zones. Further studies are needed to determine whether CGM improves outcomes in hemodialysis patients.CONCLUSIONSIn hemodialysis patients with diabetes, although MARD values were higher than traditional optimal analytic performance thresholds, error grids showed nearly all CGM values were in clinically acceptable zones. Further studies are needed to determine whether CGM improves outcomes in hemodialysis patients.
Author Siu, Man Kit Michael
Daza, Andrea C
Nguyen, Danh V
Rhee, Connie M
Novoa, Alejandra
Kalantar-Zadeh, Kamyar
Narasaki, Yoko
Peralta, Renal Amel
You, Amy S
Author_xml – sequence: 1
  givenname: Yoko
  surname: Narasaki
  fullname: Narasaki, Yoko
  organization: Tibor Rubin Veterans Affairs Medical Center, Long Beach, CA
– sequence: 2
  givenname: Kamyar
  orcidid: 0000-0002-8666-0725
  surname: Kalantar-Zadeh
  fullname: Kalantar-Zadeh, Kamyar
  organization: The Lundquist Institute at Harbor-UCLA Medical Center, Torrance, CA
– sequence: 3
  givenname: Andrea C
  surname: Daza
  fullname: Daza, Andrea C
  organization: Division of Nephrology, Department of Medicine, David Geffen School of Medicine at the University of California Los Angeles, Los Angeles, CA
– sequence: 4
  givenname: Amy S
  surname: You
  fullname: You, Amy S
  organization: Division of Nephrology, Department of Medicine, David Geffen School of Medicine at the University of California Los Angeles, Los Angeles, CA
– sequence: 5
  givenname: Alejandra
  surname: Novoa
  fullname: Novoa, Alejandra
  organization: Division of Nephrology, Department of Medicine, David Geffen School of Medicine at the University of California Los Angeles, Los Angeles, CA
– sequence: 6
  givenname: Renal Amel
  surname: Peralta
  fullname: Peralta, Renal Amel
  organization: Division of Nephrology, Hypertension, and Kidney Transplantation, Department of Medicine, University of California Irvine School of Medicine, Orange, CA
– sequence: 7
  givenname: Man Kit Michael
  surname: Siu
  fullname: Siu, Man Kit Michael
  organization: Nephrology Section, Veterans Affairs Los Angeles Healthcare System, Los Angeles, CA
– sequence: 8
  givenname: Danh V
  surname: Nguyen
  fullname: Nguyen, Danh V
  organization: Division of General Internal Medicine, University of California Irvine School of Medicine, Orange, CA
– sequence: 9
  givenname: Connie M
  orcidid: 0000-0002-9703-6469
  surname: Rhee
  fullname: Rhee, Connie M
  organization: Nephrology Section, Veterans Affairs Los Angeles Healthcare System, Los Angeles, CA
BackLink https://www.ncbi.nlm.nih.gov/pubmed/39213372$$D View this record in MEDLINE/PubMed
BookMark eNo9kLtOwzAUQC1URB8w8APIIwwBPxN7rFpokYroAGKMHNsBo8QudjL070nVwnSXc4_uPVMw8sFbAK4xuieUFg9GE5ahnPIzMMGS8oxzJkZggjCTGZeSjME0pW-EEGNCXIAxlQQPi2QCtnOt-6j0HoYaLoLvnO9Dn-Cq6XVIFr4E77oQnf-EzsO1bYNxqtknl-BWdc76LsEP133BpVOV7Wy6BOe1apK9Os0ZeH96fFuss83r6nkx32QaE84znBNDsBQ104YSJXJkcymFGg6nhhhDVG0qUaGCGKo4l6YulKmQMAhxzXhNZ-D26N3F8NPb1JWtS9o2jfJ2eKCkaNAhVnA2oHdHVMeQUrR1uYuuVXFfYlQeApaHgOUh4MDenLR91VrzT_4Vo79e4GzM
ContentType Journal Article
Copyright 2024 by the American Diabetes Association.
Copyright_xml – notice: 2024 by the American Diabetes Association.
DBID NPM
AAYXX
CITATION
7X8
DOI 10.2337/dc24-0635
DatabaseName PubMed
CrossRef
MEDLINE - Academic
DatabaseTitle PubMed
CrossRef
MEDLINE - Academic
DatabaseTitleList CrossRef
PubMed
MEDLINE - Academic
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1935-5548
ExternalDocumentID 10_2337_dc24_0635
39213372
Genre Journal Article
GrantInformation_xml – fundername: Dexcom
– fundername: NIDDK NIH HHS
  grantid: R01-DK092232
GroupedDBID ---
-ET
..I
.XZ
08P
0R~
18M
29F
2WC
4.4
53G
5GY
5RE
5RS
6PF
7RV
8R4
8R5
AAIKC
AAMNW
AAWTL
AAYEP
ABOCM
ABPPZ
ACGFO
ACGOD
ADBBV
AEGXH
AENEX
AERZD
AFOSN
AFRAH
AHMBA
AIAGR
ALIPV
ALMA_UNASSIGNED_HOLDINGS
BAWUL
BENPR
BTFSW
CS3
DIK
DU5
E3Z
EBS
EDB
EMOBN
EX3
F5P
HZ~
IAO
IEA
IGG
IHR
INH
INR
IOF
IPO
L7B
M0K
M5~
NPM
O9-
OK1
OVD
P2P
PCD
Q2X
RHF
RHI
SV3
TDI
TEORI
TR2
TWZ
VVN
WH7
WOQ
WOW
YHG
YOC
ZCG
~KM
AAYXX
CITATION
7X8
ID FETCH-LOGICAL-c1255-162d2198f4cd32a860e6998a5483d2dd2afdb8b072d3a559df7adb08d005c45f3
ISSN 0149-5992
1935-5548
IngestDate Mon Sep 02 17:06:50 EDT 2024
Wed Sep 04 12:44:13 EDT 2024
Wed Oct 09 10:24:57 EDT 2024
IsDoiOpenAccess false
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Language English
License 2024 by the American Diabetes Association.
LinkModel OpenURL
MergedId FETCHMERGED-LOGICAL-c1255-162d2198f4cd32a860e6998a5483d2dd2afdb8b072d3a559df7adb08d005c45f3
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ORCID 0000-0002-9703-6469
0000-0002-8666-0725
OpenAccessLink https://diabetesjournals.figshare.com/articles/figure/Accuracy_of_Continuous_Glucose_Monitoring_in_Hemodialysis_Patients_with_Diabetes/26527738/1/files/48308482.pdf
PMID 39213372
PQID 3099804754
PQPubID 23479
ParticipantIDs proquest_miscellaneous_3099804754
crossref_primary_10_2337_dc24_0635
pubmed_primary_39213372
PublicationCentury 2000
PublicationDate 2024-Aug-30
2024-08-30
20240830
PublicationDateYYYYMMDD 2024-08-30
PublicationDate_xml – month: 08
  year: 2024
  text: 2024-Aug-30
  day: 30
PublicationDecade 2020
PublicationPlace United States
PublicationPlace_xml – name: United States
PublicationTitle Diabetes care
PublicationTitleAlternate Diabetes Care
PublicationYear 2024
SSID ssj0004488
Score 2.507369
Snippet In the general population, continuous glucose monitoring (CGM) provides convenient and less-invasive glucose measurements than conventional self-monitored...
OBJECTIVE In the general population, continuous glucose monitoring (CGM) provides convenient and less-invasive glucose measurements than conventional...
SourceID proquest
crossref
pubmed
SourceType Aggregation Database
Index Database
Title Accuracy of Continuous Glucose Monitoring in Hemodialysis Patients With Diabetes
URI https://www.ncbi.nlm.nih.gov/pubmed/39213372
https://www.proquest.com/docview/3099804754/abstract/
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9QwELagSIhLxZvlURnErfKSxI_Yx6qlLKCiHlqpcIkc21FRtQlKswf66xnbeexCkQoXK7JkO_GXjGcm38wg9NZWlaBlaogSYJswKxIitawInLZGMWGkLH1w8tEXsThln8742VSlL0SXdOXcXF0bV_I_qEIf4OqjZP8B2XFS6IBrwBdaQBjaG2G8Z8yq9fXaPaei8TUfVp7R-qGnocfvte2jVhZu2fgokZCC5DimU_Xs1-58t6fFXK5rqkNfyF09uox1qy91rHT9tbloRnHtCZKdbsk3bd15ZGksf-qR-Hugr_RIn9S7-_M1YRP6lyDC5useiIwFl2qy4ZRUhKtY027uoiBVlBNQVeR1YjqjIdDfGj-XiOlKNlNh_3ZEjcRBMFn84MIPLfzQ2-hOlivuze6Dj5-niFgWKo6OdxZzSvmh78ZVNzWRv5gXQc04uY-2e_sA70WwH6Bbrn6I7h71DIhH6HjAHDcVnjDHPeZ4whx_r_E65njAHHvM8YDvY3R6-P5kf0H6qhjEgDLKSSoyC8eMrJixNNNSJE6Azaxhr6nNrM10ZUtZJnlmqQZ70Va5tmUiLchbw3hFn6CtuqndM4S5UEbmlFa5LBm1ThmTGqc0pUqmgqcz9GbYoeJHTH5S_IHADL0e9q4A0eT_N-nawZMXFKwPmbCcsxl6Gjd1nAbU8hSmyZ7fZIkX6N703r1EW127cq9AF-zKnQD7L7JVXdA
link.rule.ids 315,786,790,27957,27958
linkProvider Flying Publisher
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Accuracy+of+Continuous+Glucose+Monitoring+in+Hemodialysis+Patients+With+Diabetes&rft.jtitle=Diabetes+care&rft.au=Narasaki%2C+Yoko&rft.au=Kalantar-Zadeh%2C+Kamyar&rft.au=Daza%2C+Andrea+C.&rft.au=You%2C+Amy+S.&rft.date=2024-08-30&rft.issn=0149-5992&rft.eissn=1935-5548&rft_id=info:doi/10.2337%2Fdc24-0635&rft.externalDBID=n%2Fa&rft.externalDocID=10_2337_dc24_0635
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0149-5992&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0149-5992&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0149-5992&client=summon